Download PDF

1. Company Snapshot

1.a. Company Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd.


The company was founded in 2010 and is headquartered in Los Angeles, California.

Show Full description

1.b. Last Insights on PBYI

Positive drivers behind Puma Biotechnology's recent performance include its strong Q4 earnings and revenue beat, with EPS of $0.43 per share, surpassing estimates of $0.14 per share. The company's sole-marketed drug, Nerlynx, exceeded management's expectations in Q3, and the acquisition of alisertib holds promise. Additionally, the company issued fresh financial guidance for 2025, indicating confidence in its future performance.

1.c. Company Highlights

2. Puma Biotechnology's Q4 2025 Earnings: A Closer Look at Financial Performance

Puma Biotechnology reported total revenue of $75.5 million for Q4 2025, with product revenue net of $59.9 million, representing a 15% increase from $51.9 million in Q3 2025 and a 10% increase from $54.4 million in Q4 2024. The company's non-GAAP net income was $15.1 million, or $0.29 per diluted share, beating analyst estimates of $0.24. Royalty revenue was $15.6 million, driven by shipments to a partner in China. The gross to net adjustment was 27.8%, up from 25.9% in Q3 2025, primarily due to higher Medicare and Medicaid share and government chargebacks.

Publication Date: Mar -08

📋 Highlights
  • Revenue Growth: Total revenue reached $75.5M in Q4 2025, with product revenue ($59.9M) up 15% QoQ and 10% YoY.
  • Royalty Surge: Royalty revenue soared to $15.6M in Q4 2025, a 492% QoQ increase, driven by China partner shipments.
  • Inventory Build-Up: Inventory rose $5.7M in Q4 2025 after two prior declines, with NERLYNX sales up 12% QoQ (3,298 bottles).
  • Financial Performance: GAAP net income was $13.4M ($0.20/share), while non-GAAP reached $15.1M ($0.30/share).
  • 2026 Guidance: Anticipates $194–198M in NERLYNX product revenue and $20–23M in royalty revenue, with cash burn expected to rise.

Commercial Performance and NERLYNX Sales

NERLYNX ex-factory bottle sales were 3,298, representing an approximate 12% increase quarter-over-quarter and an 11% increase year-over-year. However, new prescriptions were down approximately 11.4% compared to Q3 2025, while total prescriptions were up approximately 1.4%. Demand for NERLYNX increased by about 7% quarter-over-quarter and year-over-year, driven by stronger demand growth in the specialty distribution channel, where sales grew by about 17% quarter-over-quarter and 46% year-over-year.

Pipeline Progress and Research Expenses

Puma has ongoing Phase II trials of alisertib, a drug targeting the Aurora Kinase pathway, in patients with HER2-negative, hormone receptor-positive recurrent or metastatic breast cancer and small cell lung cancer. Research and development expenses were $16.8 million in Q4 2025, driven by the progress of these clinical trials. The company expects a 30% to 35% increase in R&D expenses in 2026.

Outlook and Valuation

For fiscal year 2026, Puma anticipates net NERLYNX product revenue of $194 million to $198 million and royalty revenue of $20 million to $23 million. The company's guidance implies a relatively stable revenue profile. With a current P/E Ratio of 9.8 and an EV/EBITDA ratio of 5.2, the market appears to be pricing in moderate growth expectations. The company's Return on Equity (ROE) of 27.78% and Return on Invested Capital (ROIC) of 20.41% indicate strong profitability.

Cash Position and Operating Expenses

Puma reported cash burn of $3.1 million in Q4 2025, compared to $1.6 million in Q3 2025, due to higher operating expenses. At December 31, 2025, the company had $97.5 million in cash, cash equivalents, and marketable securities, with a distribution network maintaining approximately 4.5 weeks of inventory. Selling, General, and Administrative (SG&A) expenses increased to $18.4 million in Q4 2025, primarily due to higher non-cash charges for stock-based compensation.

3. NewsRoom

Card image cap

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

Mar -18

Source: zacks.com

Card image cap

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?

Mar -12

Source: zacks.com

Card image cap

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View

Feb -27

Source: zacks.com

Card image cap

Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript

Feb -27

Source: seekingalpha.com

Card image cap

Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates

Feb -27

Source: zacks.com

Card image cap

Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

Feb -26

Source: businesswire.com

Card image cap

Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference

Feb -23

Source: businesswire.com

Card image cap

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

Feb -12

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.33%)

6. Segments

Cancer Care Products

Expected Growth: 9.33%

Puma Biotechnology's Cancer Care Products segment growth of 9.33% is driven by increasing adoption of Nerlynx, a HER2-positive breast cancer treatment, and expanding label indications. Strong sales momentum in the US and Europe, coupled with growing demand for targeted therapies, contribute to the segment's growth. Additionally, investments in R&D and strategic partnerships enhance the company's product pipeline and market presence.

7. Detailed Products

Nerlynx

Nerlynx (neratinib) is an oral tablet used to treat adult patients with early-stage HER2-positive breast cancer, following trastuzumab-based adjuvant therapy.

8. Puma Biotechnology, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Puma Biotechnology, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.

Bargaining Power Of Customers

Puma Biotechnology, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Puma Biotechnology, Inc. relies on a few key suppliers for raw materials and services, which gives them some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to compete with established companies like Puma Biotechnology, Inc.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established companies competing for market share. Puma Biotechnology, Inc. faces intense competition from companies with similar products and technologies, which can lead to pricing pressure and reduced market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 66.15%
Debt Cost 10.41%
Equity Weight 33.85%
Equity Cost 10.41%
WACC 10.41%
Leverage 195.46%

11. Quality Control: Puma Biotechnology, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Harmony Biosciences

A-Score: 5.7/10

Value: 6.4

Growth: 9.4

Quality: 9.0

Yield: 0.0

Momentum: 5.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Puma Biotechnology

A-Score: 5.4/10

Value: 7.3

Growth: 6.0

Quality: 8.6

Yield: 0.0

Momentum: 9.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
iTeos Therapeutics

A-Score: 4.9/10

Value: 7.8

Growth: 3.6

Quality: 4.4

Yield: 0.0

Momentum: 8.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Ardelyx

A-Score: 4.4/10

Value: 6.8

Growth: 6.1

Quality: 4.7

Yield: 0.0

Momentum: 7.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Amylyx Pharmaceuticals

A-Score: 4.3/10

Value: 8.7

Growth: 3.6

Quality: 6.8

Yield: 0.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Applied Therapeutics

A-Score: 3.1/10

Value: 8.0

Growth: 6.9

Quality: 3.5

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.12$

Current Price

6.12$

Potential

-0.00%

Expected Cash-Flows